ARMP
MaterialsArmata Pharmaceuticals Inc
$9.06-0.30 (-3.21%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving ARMP Today?
No stock-specific AI insight has been generated for ARMP yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$332M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume53K
Avg Volume (10D)—
Shares Outstanding36.7M
ARMP News
20 articles- Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty StrengthYahoo Finance·May 8, 2026
- Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02Yahoo Finance·May 7, 2026
- Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"Yahoo Finance·May 4, 2026
- Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of DirectorsYahoo Finance·Apr 27, 2026
- Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial ResultsYahoo Finance·Mar 25, 2026
- Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate UpdateYahoo Finance·Mar 19, 2026
- H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA NodYahoo Finance·Mar 2, 2026
- Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02Yahoo Finance·Feb 23, 2026
- /C O R R E C T I O N -- Armata Pharmaceuticals, Inc./Yahoo Finance·Jan 13, 2026
- Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am ESTYahoo Finance·Nov 18, 2025
- Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 12, 2025
- Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- Agenus (AGEN) Misses Q3 Earnings and Revenue EstimatesYahoo Finance·Nov 10, 2025
- Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, CaliforniaYahoo Finance·Nov 10, 2025
- Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 7, 2025
- Exact Sciences (EXAS) Q3 Earnings and Revenues Beat EstimatesYahoo Finance·Nov 3, 2025
- Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?Yahoo Finance·Oct 23, 2025
- Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™Yahoo Finance·Oct 22, 2025
- Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™Yahoo Finance·Oct 14, 2025
- Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?Yahoo Finance·Oct 6, 2025
All 20 articles loaded
Price Data
Open$8.88
Previous Close$9.36
Day High$10.35
Day Low$8.78
52 Week High—
52 Week Low—
Fundamentals
Market Cap$332M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume53K
Avg Volume (10D)—
Shares Outstanding36.7M
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeAMEX
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—